Your browser doesn't support javascript.
loading
Demonstration of the first-pass metabolism in the skin of the hair dye, 4-amino-2-hydroxytoluene, using the Chip2 skin-liver microphysiological model.
Tao, Thi Phuong; Brandmair, Katrin; Gerlach, Silke; Przibilla, Julia; Géniès, Camille; Jacques-Jamin, Carine; Schepky, Andreas; Marx, Uwe; Hewitt, Nicola J; Maschmeyer, Ilka; Kühnl, Jochen.
Affiliation
  • Tao TP; Contract development, TissUse GmbH, Berlin, Germany.
  • Brandmair K; Front End Innovation, department of toxicology, Beiersdorf AG, Hamburg, Germany.
  • Gerlach S; Front End Innovation, department of toxicology, Beiersdorf AG, Hamburg, Germany.
  • Przibilla J; ADMET & in vitro Pharmacology, Pharmacelsus GmbH, Saarbrücken, Germany.
  • Géniès C; Department of applied research: pharmacology, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
  • Jacques-Jamin C; Department of applied research: pharmacology, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
  • Schepky A; Front End Innovation, department of toxicology, Beiersdorf AG, Hamburg, Germany.
  • Marx U; Contract development, TissUse GmbH, Berlin, Germany.
  • Hewitt NJ; ADME Task Force, Cosmetics Europe, Auderghem, Belgium.
  • Maschmeyer I; Contract development, TissUse GmbH, Berlin, Germany.
  • Kühnl J; Front End Innovation, department of toxicology, Beiersdorf AG, Hamburg, Germany.
J Appl Toxicol ; 41(10): 1553-1567, 2021 10.
Article in En | MEDLINE | ID: mdl-33594739
ABSTRACT
We used TissUse's HUMIMIC Chip2 microfluidic model, incorporating reconstructed skin models and liver spheroids, to investigate the impact of consumer-relevant application scenarios on the metabolic fate of the hair dye, 4-amino-2-hydroxytoluene (AHT). After a single topical or systemic application of AHT to Chip2 models, medium was analysed for parent and metabolites over 5 days. The metabolic profile of a high dose (resulting in a circuit concentration of 100 µM based on 100% bioavailability) of AHT was the same after systemic and topical application to 96-well EpiDerm™ models. Additional experiments indicated that metabolic capacity of EpiDerm™ models were saturated at this dose. At 2.5 µM, concentrations of AHT and several of its metabolites differed between application routes. Topical application resulted in a higher Cmax and a 327% higher area under the curve (AUC) of N-acetyl-AHT, indicating a first-pass effect in the EpiDerm™ models. In accordance with in vivo observations, there was a concomitant decrease in the Cmax and AUC of AHT-O-sulphate after topical, compared with systemic application. A similar alteration in metabolite ratios was observed using a 24-well full-thickness skin model, EpiDermFT™, indicating that a first-pass effect was also possible to detect in a more complex model. In addition, washing the EpiDermFT™ after 30 min, thus reflecting consumer use, decreased the systemic exposure to AHT and its metabolites. In conclusion, the skin-liver Chip2 model can be used to (a) recapitulate the first-pass effect of the skin and alterations in the metabolite profile of AHT observed in vivo and (b) provide consumer-relevant data regarding leave-on/rinse-off products.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Skin / Cresols / Hair Dyes / Liver / Aniline Compounds Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Appl Toxicol Year: 2021 Type: Article Affiliation country: Germany

Full text: 1 Database: MEDLINE Main subject: Skin / Cresols / Hair Dyes / Liver / Aniline Compounds Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Appl Toxicol Year: 2021 Type: Article Affiliation country: Germany